“Research use only” is a reason to pause.

Do not read the label as clearance

As of September 2026, labeling a product “research use only” gives no evidence of approval to treat people.

If the offer leaves you wondering whether a product is meant for patients or for a laboratory, pause the comparison. Ask for the actual medicine and its approval status.

The FDA has addressed human-use offers

Reviewing medicines is work the Food and Drug Administration (FDA) does for the U.S. government.

FDA guidance checked in September 2026 urges people to stay away from weight-loss products marketed for human use under research labels.

According to FDA, these products have unknown quality and could damage health.

Ask about care for your concern before comparing products on a research page.

Compounding is not a catch-all answer

Compounding means preparing a medicine to order.

It does not turn every research chemical into a treatment option.

Retatrutide and cagrilintide are drug names you may see in weight-loss offers. As of September 2026, no FDA-approved medicine contains either ingredient, and using either one in compounding is barred by federal law.

Ask a licensed doctor or other prescriber about care options for your concern. There is no need to begin by choosing a chemical from a research page.